(NASDAQ: TMDX) Transmedics Group's forecast annual revenue growth rate of 28.57% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 5.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 6.49%.
Transmedics Group's revenue in 2023 is $191,824,000.On average, 4 Wall Street analysts forecast TMDX's revenue for 2023 to be $7,489,675,750, with the lowest TMDX revenue forecast at $7,440,410,374, and the highest TMDX revenue forecast at $7,548,147,778. On average, 4 Wall Street analysts forecast TMDX's revenue for 2024 to be $10,665,513,221, with the lowest TMDX revenue forecast at $9,793,656,446, and the highest TMDX revenue forecast at $11,443,083,444.
In 2025, TMDX is forecast to generate $12,850,721,591 in revenue, with the lowest revenue forecast at $10,603,972,310 and the highest revenue forecast at $14,482,061,765.